POMALYST® (pomalidomide) is a thalidomide analogue indicated, in combination with dexamethasone, for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Safety profile of POMALYST® (pomalidomide) + dex + daratumumab (DPd).1

- Infusion reaction includes terms determined by investigators to be related to infusion. Severe infusion reactions included bronchospasm, dyspnea, laryngeal edema, pulmonary edema, hypoxia, and hypertension. Other adverse infusion reactions were nasal congestion, cough, chills, throat irritation, vomiting, and nausea.
- Acute tonsillitis, bronchitis, laryngitis, nasopharyngitis, pharyngitis, respiratory syncytial virus infection, rhinitis, sinusitis, tonsillitis, upper-respiratory tract infection.
- Cough, productive cough, allergic cough.
- Dyspnea, dyspnea exertional.
13% of patients discontinued treatment due
to adverse reaction(s).1
- Median treatment duration: 6 months (range: 0.03-16.9 months)
- Neutropenia (95%) was the most commonly reported adverse reaction
- 44% of patients presented with Grade 1 or 2 neutropenia at baseline2
- The overall incidence of serious adverse reactions was 49%
- Serious adverse reactions reported in ≥5% of patients included pneumonia (7%)

Information about DPd does not appear in the POMALYST full Prescribing Information. Please see the daratumumab full Prescribing Information for a discussion of Important Safety Information at www.darzalexhcp.com/iv.
dara, daratumumab; dex, dexamethasone; DPd, POMALYST + dexamethasone + daratumumab; IV, intravenous.
References: 1. Daratumumab [package insert]. Horsham, PA: Janssen Biotech, Inc. 2. Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood. 2017;130(8):974-981. 3. POMALYST [package insert]. Summit, NJ: Celgene Corp.